Ocrelizumab was found to be effective and safe therapy in relapsing-remitting, primary-progressive and secondary-progressive multiple sclerosis patients. Performed on 153 patients (mean age: 41.9 years; 60% females; mean EDSS: 3.5), this study provided first real-world effectiveness and safety data and the possible predictors of treatment response. After 2 years, percentage disability worsening-free patients were 90.5%, 64.7% and 68.8%, of MRI-activity-free patients 67.1%, 72.7% and 81.3% and of NEDA-3 patients 62.1%, 54.6% and 55.1% for relapsing-remitting, primary-progressive and secondary-progressive multiple sclerosis, respectively. Reduced risk of disability worsening was associated with lower baseline EDSS, shorter disease duration, younger age, higher annualized relapse rate and baseline MRI activity. Previous disease-modifying therapy exposure and baseline MRI-activity were linked to increased risk of radiological activity. NEDA-3 was achieved more often in treatment-naïve patients. At 6 months, CD8+ cell count was higher in early inflammatory patients than stable patients (464 vs 339; p=0.001) indicating its correlation to early inflammatory activity. The most common adverse events observed were upper respiratory tract infections.
